MX2010003660A - Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo. - Google Patents

Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.

Info

Publication number
MX2010003660A
MX2010003660A MX2010003660A MX2010003660A MX2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A MX 2010003660 A MX2010003660 A MX 2010003660A
Authority
MX
Mexico
Prior art keywords
skin
remedy
active ingredient
acid addition
addition salt
Prior art date
Application number
MX2010003660A
Other languages
English (en)
Inventor
Shinji Ona
Koichiro Takeshita
Naoki Ando
Masahiro Yamashita
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2010003660A publication Critical patent/MX2010003660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

El objeto de esta invención es proporcionar una medicina novedosa útil para terapia para mejorar las propiedades de la piel tales como secado de la piel, endurecimiento de la piel y el oscurecimiento de la piel involucrado en hiperqueratinosis ( capa de queratina engrosada ) mediante un efecto de retención de humedad de piel contra el declive de las funciones de la piel traídas por varias causas. Esta invención proporciona un agente terapéutico de mejoramiento de propiedades de la piel que comprende un compuesto teniendo un esqueleto de morfinano específico tipificado por un compuesto 1 representado por la siguiente fórmula (II) o cualquiera de sus sales de adición de ácido farmacológicamente permisibles como un ingrediente activo.
MX2010003660A 2007-10-05 2008-10-03 Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo. MX2010003660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007262015 2007-10-05
PCT/JP2008/068092 WO2009044883A1 (ja) 2007-10-05 2008-10-03 モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬

Publications (1)

Publication Number Publication Date
MX2010003660A true MX2010003660A (es) 2010-08-10

Family

ID=40526303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003660A MX2010003660A (es) 2007-10-05 2008-10-03 Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.

Country Status (14)

Country Link
US (1) US20100222309A1 (es)
EP (1) EP2196206B8 (es)
JP (1) JP5613417B2 (es)
KR (1) KR101173509B1 (es)
CN (1) CN101848714B (es)
AU (1) AU2008308005B2 (es)
BR (1) BRPI0817804A8 (es)
CA (1) CA2702032C (es)
ES (1) ES2748274T3 (es)
MX (1) MX2010003660A (es)
PL (1) PL2196206T3 (es)
RU (1) RU2440117C1 (es)
TW (1) TWI453020B (es)
WO (1) WO2009044883A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2554857C2 (ru) * 2010-01-29 2015-06-27 Торэй Индастриз, Инк. Терапевтическое или профилактическое средство для заболеваний желчных путей
KR101960107B1 (ko) * 2010-10-19 2019-03-19 메모리얼 슬로안 케터링 캔서 센터 통증의 치료를 위한 ４,５에이-에폭시모르피난의 ６-아미도 유도체
ES2586655T3 (es) 2011-01-31 2016-10-18 Toray Industries, Inc. (-)-17-(ciclopropilmetil)-3,14beta-dihidroxi-4,5alfa-epoxi-6beta-[N-metil-trans-3-(3-furil)acrilamido]morfinano para su utilización en el tratamiento o prevención de la caquexia por cáncer
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
TW201441199A (zh) 2012-12-28 2014-11-01 Purdue Pharma Lp 經取代之嗎啡喃類及其用途
EP4212532A3 (en) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
US11082591B2 (en) 2017-03-03 2021-08-03 Amazon Technologies, Inc. Solar-charging mounting bracket for audio/video recording and communication devices
WO2019171333A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
EP4173624A1 (en) * 2020-06-30 2023-05-03 Toray Industries, Inc. Ameliorating agent or prophylactic agent for muscle weakness symptom in disease or syndrome associated with metabolic disorder
EP4334298A1 (en) 2021-06-14 2024-03-13 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923875A (en) * 1989-07-10 1990-05-08 Baker Cummins Pharmaceuticals, Inc. Method for treatment of mast cell-mediated dermatologic disorders
JP2521853B2 (ja) 1990-07-25 1996-08-07 タカラベルモント株式会社 化粧料
EP0577847B1 (en) 1992-01-23 1998-10-14 Toray Industries, Inc. Morphinan derivative and medicinal use
CA2144770C (en) 1993-07-19 2006-02-28 Hiroshi Nagase Brain cell protective agent
WO1995003308A1 (en) * 1993-07-23 1995-02-02 Toray Industries, Inc. Morphinan derivative and medicinal use
JPH07187990A (ja) 1993-12-24 1995-07-25 Toshiko Yamamoto 化粧料
ATE291429T1 (de) * 1996-11-25 2005-04-15 Toray Industries Mittel gegen juckreiz
US5834480A (en) 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
WO1999005146A1 (fr) * 1997-07-25 1999-02-04 Toray Industries, Inc. Remedes contre l'hyponatremie
WO1999011289A1 (fr) 1997-09-02 1999-03-11 Toray Industries, Inc. Remedes contre la toxicomanie
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
CA2383146C (en) 1999-08-24 2010-11-16 Hiroshi Nagase Therapeutic agent for neuropathic pain and neuropathic pain animal model
ES2319265T3 (es) 2001-03-30 2009-05-06 Toray Industries, Inc. Farmacos para el sindrome de piernas inquietas.
US7652025B2 (en) 2001-05-08 2010-01-26 Toray Industries, Inc. Remedies for sepsis
JP2004107209A (ja) 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
WO2004074277A1 (ja) * 2003-02-19 2004-09-02 Hisamitsu Medical Co., Ltd. Ｎ－アリール又はｎ－ヘテロアリールピペラジン誘導体及びそれを含有する医薬
JP2004352714A (ja) 2003-05-08 2004-12-16 Kyorin Pharmaceut Co Ltd 新規な４−（２−フロイル）アミノピペリジン誘導体
JP4381157B2 (ja) * 2004-02-03 2009-12-09 久光製薬株式会社 ２，２−ジフェニル−１−エタノン誘導体及びそれを含有する医薬
PL1870413T3 (pl) * 2005-03-10 2013-12-31 Toray Industries Środek przeciwświądowy w przypadku świądu spowodowanego stwardnieniem rozsianym
CA2609985A1 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction

Also Published As

Publication number Publication date
US20100222309A1 (en) 2010-09-02
JPWO2009044883A1 (ja) 2011-02-10
ES2748274T3 (es) 2020-03-16
AU2008308005A1 (en) 2009-04-09
BRPI0817804A2 (pt) 2016-10-11
EP2196206A1 (en) 2010-06-16
WO2009044883A1 (ja) 2009-04-09
JP5613417B2 (ja) 2014-10-22
KR101173509B1 (ko) 2012-08-14
EP2196206A4 (en) 2010-09-22
TW200927116A (en) 2009-07-01
CA2702032A1 (en) 2009-04-09
TWI453020B (zh) 2014-09-21
EP2196206B8 (en) 2019-11-13
AU2008308005B2 (en) 2012-06-07
CN101848714A (zh) 2010-09-29
EP2196206B1 (en) 2019-07-17
PL2196206T3 (pl) 2020-02-28
KR20100049683A (ko) 2010-05-12
CN101848714B (zh) 2014-08-20
CA2702032C (en) 2013-04-02
RU2440117C1 (ru) 2012-01-20
BRPI0817804A8 (pt) 2017-04-18

Similar Documents

Publication Publication Date Title
MX2010003660A (es) Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
TW200728307A (en) Novel spirochromanone derivatives
WO2007002013A3 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2008096841A1 (ja) 二量化シクロ誘導体
BRPI0514735B8 (pt) derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
NZ594184A (en) Skin treatment
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
WO2008133297A1 (ja) ジスキネジアの治療または予防剤
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва
MA33619B1 (fr) Agent thérapeutique pour des troubles de l'anxiété
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2005079769A3 (en) Piperazine derivatives for the treatment of endometriosis
MXPA05014127A (es) Uso de derivados de biciclo[2.2.1]heptano para la preparacion de composiciones farmaceuticas neuroprotectoras.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal